Form 4: Crinetics Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on March 20, 2024.
Summary
- On March 20, 2024, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 14,375 shares of common stock at a price of $16.89 per share.
- Following the exercise of these options, Pizzuti sold 15,089 shares of common stock in open market transactions.
- The sales were executed at prices ranging from $42.70 to $43.77 per share, with a volume-weighted average sales price of $43.28 and $45.89 per share.
- After these transactions, Pizzuti directly owns 27,786 shares of Crinetics Pharmaceuticals common stock and holds options to purchase 191,667 additional shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to monitor.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of earliest transaction: exercise of stock options and sale of shares. |
| 03/22/2024 | Date of signature on the Form 4 filing. |
| 09/30/2023 | 25% of the shares subject to the option vest on this date. |
| 10/10/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.